AffiliationDepartment of Endocrinology, Christie Hospital NHS Trust, Wilmslow Road, Manchester M20 4BX, UK. email@example.com
MetadataShow full item record
AbstractIn the human male, testosterone is the major circulating androgen. More than 95% of circulating testosterone is secreted by the testis with a production rate of 6-7 mg/day. The clinical effects of androgens are numerous, and testosterone deficiency is associated with a number of clinical abnormalities. Overt hypogonadism results in reductions in bone mineral density, alterations in body composition and effects on mood, aggressive behaviour, cognitive function, sexual function and several factors important for cardiovascular risk. Androgen replacement in this context is clearly beneficial, and numerous studies have demonstrated improvements in bone and muscle mass, reductions in body fat, and positive effects on quality of life following treatment. The benefits of therapy in men with milder degrees of hypogonadism, and elderly men with "physiological" testosterone deficiency, are less clear-cut, and the appropriate biochemical cut-off below which replacement should be offered has not been clearly defined. Several options are available for androgen replacement in adult men. Oral testosterone, intramuscular injections, subcutaneous implants and transdermal therapy have all been used. Each mode of delivery has advantages and drawbacks and the choice between them will often depend on patient reference. Recent advances include the development of longer-acting intramuscular preparations, which offer more stable androgen levels with fairly infrequent injections, and testosterone gel which appears to provide transdermal replacement without a high incidence of skin reactions. This article will examine the evidence concerning the impact of male hypogonadism and the response to androgen therapy. The question of who to treat will be addressed with particular reference to mild hypogonadism and hypogonadism in the elderly. Finally, an overview of the different modes of replacement therapy will be presented.
CitationTestosterone deficiency and replacement. 2001, 56 Suppl 1:86-92 Horm. Res.
- Randomized placebo-controlled trial of testosterone replacement in men with mild Leydig cell insufficiency following cytotoxic chemotherapy.
- Authors: Howell SJ, Radford JA, Adams JE, Smets EM, Warburton R, Shalet SM
- Issue date: 2001 Sep
- Negative Impact of Testosterone Deficiency and 5α-Reductase Inhibitors Therapy on Metabolic and Sexual Function in Men.
- Authors: Traish AM
- Issue date: 2017
- Testosterone replacement therapy in male hypogonadism.
- Authors: Byrne M, Nieschlag E
- Issue date: 2003 May
- Testosterone treatment in the aging male: myth or reality?
- Authors: Nigro N, Christ-Crain M
- Issue date: 2012
- Current and future testosterone delivery systems for treatment of the hypogonadal male.
- Authors: Pfeil E, Dobs AS
- Issue date: 2008 Apr